Crescent Grove Advisors LLC Sells 8,454 Shares of iShares Biotechnology ETF (NASDAQ:IBB)

Crescent Grove Advisors LLC trimmed its holdings in shares of iShares Biotechnology ETF (NASDAQ:IBB) by 19.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 34,346 shares of the financial services provider’s stock after selling 8,454 shares during the quarter. Crescent Grove Advisors LLC owned approximately 0.07% of iShares Biotechnology ETF worth $4,541,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Darwin Wealth Management LLC purchased a new position in iShares Biotechnology ETF during the third quarter valued at approximately $29,000. Highline Wealth Partners LLC bought a new stake in shares of iShares Biotechnology ETF during the 3rd quarter valued at $30,000. Ashton Thomas Securities LLC purchased a new position in shares of iShares Biotechnology ETF during the 3rd quarter valued at $36,000. Modus Advisors LLC bought a new position in iShares Biotechnology ETF in the 4th quarter worth $41,000. Finally, Voisard Asset Management Group Inc. purchased a new stake in iShares Biotechnology ETF in the 3rd quarter worth $59,000. Institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Price Performance

NASDAQ:IBB opened at $137.30 on Friday. The business’s 50-day simple moving average is $136.04 and its two-hundred day simple moving average is $141.80. iShares Biotechnology ETF has a 52 week low of $123.60 and a 52 week high of $150.57.

iShares Biotechnology ETF Cuts Dividend

The firm also recently declared a dividend, which was paid on Friday, December 20th. Investors of record on Tuesday, December 17th were issued a $0.0624 dividend. The ex-dividend date of this dividend was Tuesday, December 17th.

About iShares Biotechnology ETF

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.